AIM: To investigate whether microvessel density (MVD) is related with prognosis in gastric cancer patients, and the expression of cyclooxygenase-2 (COX-2) and vessel endothelial growth factor (VEGF) so as to determine the possible role of COX-2 and VEGF in gastric cancer angiogenesis. METHODS: Forty-seven formalin-fixed paraffin-embedded tissue samples of gastric cancer were evaluated for COX-2, VEGF by immunohitochemical staining. To assess tumor angiogenesis, MVD was determined by immunohitochemical staining of endothelial protein factor VIII-related antigen. The relationship among COX-2 and VEGF expression, MVD, and clinicopathologic parameters was analyzed. RESULTS: Among the 67 samples, high MVD was significantly associated with lymph node metastasis and poor survival. Multivariate survival analysis showed that MVD value and lymph node metastasis were independent prognostic factors. The expression rate of COX-2 and VEGF was significantly higher than that of the adjacent tissues. COX-2 and VEGF expression in gastric cancer was significantly correlated with tumor differentiation and depth of invasion, but not with survival. The mean MVD value of COX-2 or VEGF positive tumors was higher than that of COX-2 or VEGF negative tumors. A significant correlation was found between the expressions of COX-2 and VEGF. CONCLUSION: MVD may be one of the important prognostic factors for gastric cancer patients. COX-2 and VEGF may play an important role in tumor progression by stimulating angiogenesis. VEGF might play a main role in the COX-2 angiogenic pathway. The inhibition of angiogenesis or COX-2, VEGF activity may have an important therapeutic benefit in the control of gastric cancer.
AIM: To investigate whether microvessel density (MVD) is related with prognosis in gastric cancerpatients, and the expression of cyclooxygenase-2 (COX-2) and vessel endothelial growth factor (VEGF) so as to determine the possible role of COX-2 and VEGF in gastric cancer angiogenesis. METHODS: Forty-seven formalin-fixed paraffin-embedded tissue samples of gastric cancer were evaluated for COX-2, VEGF by immunohitochemical staining. To assess tumor angiogenesis, MVD was determined by immunohitochemical staining of endothelial protein factor VIII-related antigen. The relationship among COX-2 and VEGF expression, MVD, and clinicopathologic parameters was analyzed. RESULTS: Among the 67 samples, high MVD was significantly associated with lymph node metastasis and poor survival. Multivariate survival analysis showed that MVD value and lymph node metastasis were independent prognostic factors. The expression rate of COX-2 and VEGF was significantly higher than that of the adjacent tissues. COX-2 and VEGF expression in gastric cancer was significantly correlated with tumor differentiation and depth of invasion, but not with survival. The mean MVD value of COX-2 or VEGF positive tumors was higher than that of COX-2 or VEGF negative tumors. A significant correlation was found between the expressions of COX-2 and VEGF. CONCLUSION: MVD may be one of the important prognostic factors for gastric cancerpatients. COX-2 and VEGF may play an important role in tumor progression by stimulating angiogenesis. VEGF might play a main role in the COX-2 angiogenic pathway. The inhibition of angiogenesis or COX-2, VEGF activity may have an important therapeutic benefit in the control of gastric cancer.
Authors: Shan Zha; Vasan Yegnasubramanian; William G Nelson; William B Isaacs; Angelo M De Marzo Journal: Cancer Lett Date: 2004-11-08 Impact factor: 8.679
Authors: C Lackner; Z Jukic; O Tsybrovskyy; G Jatzko; V Wette; G Hoefler; M Klimpfinger; H Denk; K Zatloukal Journal: Virchows Arch Date: 2004-06-30 Impact factor: 4.064
Authors: M S Al-Moundhri; I Al-Hadabi; K Al-Mawaly; S Kumar; F A R Al-Lawati; G Bhatnager; S Kuruvila; A Al-Hamdani; S M El-Sayed; B Al-Bahrani Journal: Med Oncol Date: 2011-11-03 Impact factor: 3.064
Authors: Cristina Angelescu; Florin Burada; Mihai Ioana; Radu Angelescu; Emil Moraru; Anca Riza; Sanda Marchian; Francisc Mixich; Mihai Cruce; Adrian Săftoiu Journal: Clin Transl Oncol Date: 2012-08-08 Impact factor: 3.405
Authors: Joanna M Brell; Smitha S Krishnamurthi; Milind Javle; Joel Saltzman; Ira Wollner; Robert Pelley; Afshin Dowlati; Belagodu N Kantharaj; Mark D Schluchter; Linda Rath; S Percy Ivy; Scot C Remick Journal: Cancer Chemother Pharmacol Date: 2008-08-01 Impact factor: 3.333
Authors: Seong Ran Jeon; Joo Young Cho; Gene Hyun Bok; Tae Hee Lee; Hyun Gun Kim; Won Young Cho; So Young Jin; Yeon Soo Kim Journal: World J Gastroenterol Date: 2012-09-07 Impact factor: 5.742
Authors: Hong Shi; Xiu-Hua Yu; Xin-Zhang Guo; Yuan Guo; Hong Zhang; Bin Qian; Zhang-Rui Wei; Li Li; Xian-Chen Wang; Zi-Xiang Kong Journal: World J Gastroenterol Date: 2012-08-21 Impact factor: 5.742